BioNTech SE (BNTX) Change in Accured Expenses (2018 - 2019)
BioNTech SE (BNTX) posted Change in Accured Expenses of $66.3 million for Q4 2019, up 600.81% sequentially from $9.5 million in Q4 2018, and up 600.81% YoY from $9.5 million in Q4 2018.
BioNTech SE (BNTX) Change in Accured Expenses (2018 - 2019) Analysis & Trends
BioNTech SE has reported Change in Accured Expenses for 2 years, with the latest figure at $66.3 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | -13.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 66.33 Mn |
| Dec 31, 2019 | 66.33 Mn |
| Dec 31, 2018 | 9.46 Mn |
| Dec 31, 2018 | 9.46 Mn |